Skip to main content
. Author manuscript; available in PMC: 2010 Aug 10.
Published in final edited form as: Semin Hematol. 2008 Apr;45(2):90–94. doi: 10.1053/j.seminhematol.2008.02.003

Table 1.

Published Trials Comparing Rituximab Plus CHOP to CHOP for Patients with DLBCL

Study Group Study Type N Follow-up PFS
 OS
R-CHOP CHOP R-CHOP CHOP
BCCA5 Registry 292 2yr 68% 51% 78% 52%
US intergroup6 RCT 632 3yr 52% 39% 67% 58%
International7 RCT 824 3yr 79% 59% 93% 84%
GELA8 RCT 399 5yr 54% 30% 58% 45%

NOTE. All differences in PFS and OS are statistically significant at the .05 level.

Abbreviations: BCCA, British Columbia Cancer Agency; GELA, Group d’Etude des Lymphomas de I’Adulte.